Arsenic trioxide (As 2 O 3 ) was shown to induce complete remission in a high proportion of patients with relapsed and all-trans retinoic acid (ATRA)-resistant acute promyelocytic leukemia (APL). 1 The clinical response to As 2 O 3 is associated with the induction of nonterminal cytodifferentiation and the activation of cysteine proteases (caspases) that are characteristic of apoptosis. We have recently found that vitamin A derivatives, retinoids such as ATRA, exert anticoagulant effects by upregulating thrombomodulin (TM) and downregulating tissue factor (TF) expression in APL and acute monoblastic leukemia cells. 2, 3 The effect of ATRA explains the rapid improvement of disseminated intravascular coagulation syndrome (DIC), which is a complication, observed in almost all APL patients. Since the mechanism of action of As 2 O 3 does not involve its binding to retinoic acid receptors (RARs), in contrast to that of retinoic acids (RAs), 4 we have examined the regulation of TM and TF expression in APL cell line, NB4 cells treated with As 2 O 3 alone or in combination with ATRA. Our data generally support a very recent report by Zhu et al, 5 which has appeared in this journal.
CORRESPONDENCE

Arsenic trioxide (As 2 O 3 ) gradually downregulates tissue factor expression without affecting thrombomodulin expression in acute promyelocytic leukemia cells
TO THE EDITOR Arsenic trioxide (As 2 O 3 ) was shown to induce complete remission in a high proportion of patients with relapsed and all-trans retinoic acid (ATRA)-resistant acute promyelocytic leukemia (APL). 1 The clinical response to As 2 O 3 is associated with the induction of nonterminal cytodifferentiation and the activation of cysteine proteases (caspases) that are characteristic of apoptosis. We have recently found that vitamin A derivatives, retinoids such as ATRA, exert anticoagulant effects by upregulating thrombomodulin (TM) and downregulating tissue factor (TF) expression in APL and acute monoblastic leukemia cells. 2, 3 The effect of ATRA explains the rapid improvement of disseminated intravascular coagulation syndrome (DIC), which is a complication, observed in almost all APL patients. Since the mechanism of action of As 2 O 3 does not involve its binding to retinoic acid receptors (RARs), in contrast to that of retinoic acids (RAs), 4 we have examined the regulation of TM and TF expression in APL cell line, NB4 cells treated with As 2 O 3 alone or in combination with ATRA. Our data generally support a very recent report by Zhu et al, 5 which has appeared in this journal.
After we began treating NB4 cells with As 2 O 3 , we replaced half of NB4 cell-suspended medium by fresh medium containing 10% fetal calf serum and 1 M As 2 O 3 every 3 days. Such a culture condition avoids serum starvation, makes cells more resistant to apoptosis induced by As 2 O 3 and keeps cell concentration rather more constant than that previously reported in studies in vitro. Treatment of NB4 cells with 1 M As 2 O 3 for 14 days induced morphological changes, such as condensed chromatin, smaller nuclei, a decreased nuclei/cytoplasm ratio, and the appearance of granules in the cytoplasm. About 30% of the cells were found to resemble myelocyte morphologically, and the maturation stage of the remainder of the cells still corresponded to the promyelocyte stage. Less than 10% of total cells appeared apoptotic showing nuclear fragmentation. More than 90% of cells still kept alive by Trypan blue exclusion method. Viable cell numbers were counted and adjusted.
We measured the changes in the total levels of TF and TM antigens in NB4 cells incubated with 1 M As 2 O 3 (from Sigma, St Louis, MO, USA). The TF antigen levels in cell lysates treated with As 2 O 3 decreased more gradually and modestly (1.37 ± 0.04 at 7 days, 0.81 ± 0.04 at 14 days vs control 2.20 ± 0.12 ng/10 7 cells) compared to those in cell lysates treated with 0.1 M ATRA. ATRA induced a marked decrease in TF expression at 1 day (0.40 ± 0.02 ng/10 7 cells) as reported before.
2,3
On the other hand, As 2 O 3 did not induce a change in TM antigen levels even after treatment for 14 days (2.46 ± 0.16 vs control 2.69 ± 0.10 ng/10 7 cells). ATRA markedly increased the TM antigen level (32.4 ± 4.9 ng/10 7 cells) at 1 day as reported. 2, 3 NB4 cells were treated with As 2 O 3 and the cell surface TF and TM activities were measured. Treatment of NB4 cells with As 2 O 3 for 3 days resulted in a decrease in cell surface TF activity, which occurred more gradually, and not to the extent induced by 0.1 M ATRA treatment for 1 day. ATRA promptly induced downregulation of TF activity as previously reported. 3 Treatment for a 7-day period was required to decrease the TF activity to about one-third of the pretreatment levels of the NB4 cells ( Figure 1a) . 2, 3 The percent decrease in cell surface TF activity after 7 days was two-fold greater than that in TF antigen levels in total cell lysates ( Figure 1a ). Cell surface TM activity was measured as the degree of acceleration of thrombin-catalyzed protein C activation. 
Figure 1
Changes in TF and TM cofactor activity on the surface of NB4 cells after exposure to As 2 O 3 . (a) NB4 cells were exposed to 1 M As 2 O 3 for 1, 3 or 7 days, or exposed to 0.1 M ATRA for 1 day. Cell surface TF activity (assay of 10 6 cells) was determined on the basis of normal plasma-based one-stage recalcification clotting time and quantitatively measured by reference to standard curves constructed using human placenta TF as described previously.
3 (b) Cell surface TM cofactor activity in cell suspensions was determined as described previously. 2, 3 Basal ⌬OD405 nm/min levels were 0.033 ± 0.002/min/5 × 10 6 cells (0.72 ± 0.04 APC nM/min/10 6 cells). These assays were repeated independently five times and the results are expressed as the mean ± s.d. The difference between the TF cofactor activity on the surface of NB4 cells treated with As 2 O 3 for 7 days and that of untreated cells is statistically significant (P = 0.0005). 
Figure 2
Effect of As 2 O 3 and ATRA in combination on the TF (a) and TM (b) activities on the surface of NB4 cells. NB4 cells were pretreated with 1 M As 2 O 3 for 1 day, and subsequently exposed to As 2 O 3 and 0.1 M ATRA for 1 more day (As + ATRA). The effects of As 2 O 3 treatment for a 2-day period and ATRA treatment for a 1-day period of NB4 cells are also shown. These assays were repeated independently four times. The inhibitory effect of pretreatment with As 2 O 3 on TM upregulation by ATRA was significant (P = 0.02).
Figure 3
RT-PCR analysis of TF and TM mRNAs in NB4 cells treated with As 2 O 3 . Total RNAs were extracted from cultured NB4 cells after exposure to 1 M As 2 O 3 for 7 or 14 days. RT-PCR analysis of TF (a) or TM (b) mRNA was performed as previously described. 3 Base pair markers are shown to the left. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was used as a control for assessing the quantity of mRNA.
To examine the changes in TF and TM mRNA levels, NB4 cells were treated with As 2 O 3 for 7 or 14 days. In cells treated with As 2 O 3 , the level of expression of TF mRNA decreased more gradually than that observed in cells treated with ATRA (Figure 3a) , 3 and As 2 O 3 did not induce any change in the level of expression of TM mRNA (Figure 3b tive of coagulopathy and hyperfibrinolysis fibrinogen/fibrin degradation products (FDP) and D-dimers gradually decreased and thus clinical improvement of DIC was also observed. 1, 5 Whereas APL patients treated with ATRA show rapid improvement of coagulopathy within a few days, DIC in patients treated with As 2 O 3 improves in 1 week or more (personal communication by Dr Zhou Jin, First College of Harbin Medical University, Harbin, People's Republic of China). The effect of As 2 O 3 in inducing modest TF downregulation without TM upregulation, as shown in this study, seems to be compatible with the gradual and slow improvement of DIC in patients treated with As 2 O 3 .
Since As 2 O 3 may neither interact nor activate a RA-responsive element in the TM gene, it may not be able to upregulate TM expression. The effects of As 2 O 3 could be due to the rapid modulation and degradation of PML/RAR␣ fusion protein induced by As 2 O 3 . As a result of the disappearance of the PML/RAR␣ fusion protein, which might have some stimulatory effect on TF gene expression in the APL cell line NB4, the level of TF expression may gradually decrease. Whereas ATRA has a positive-or negative-acting effect by inducing the formation of complexes with its receptors, As 2 O 3 does not form such complexes to directly regulate TM and TF gene expression. The repression of TF by As 2 O 3 , therefore, progresses more slowly than that in the case of ATRA.
For the effect on cell differentiation induced by ATRA, the presence of the PML/RAR␣ fusion protein is rather necessary. Also, it has been reported that As 2 O 3 inhibits ATRA-induced, rapid differentiation of NB4 cells when applied in vitro in combination with ATRA. 6 In our study, pretreatment with As 2 O 3 partially abolished the rapid TM upregulation and TF downregulation effects of ATRA. The rapid disappearance of the PML/RAR␣ fusion protein might interfere with the action of ATRA on TM and TF regulation. These phenomena indicate that As 2 O 3 influences the RA-induced pathway for regulation of these genes. Whereas the modulation of TF by As 2 O 3 appears to occur in parallel with cell differentiation or apoptosis, further investigations are necessary to elucidate the precise mechanism involved in these functions. 1 1 Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?
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TO THE EDITOR During the last decade several groups have reported that acute myeloid leukemia (AML) in children with Down's syndrome (DS) has a significantly better outcome than AML in other children. 1, 2 In acute lymphoblastic leukemia (ALL), on the other hand, the clinical outcome tends to be worse for DS than for non-DS children. 3, 4 The reason for this difference between AML and ALL is not known.
In an ongoing study we prepared leukemic cells at diagnosis from 62 children with AML and 222 children with ALL for test of in vitro sensitivity to cytotoxic drugs. Five children with AML (8%) and five children with ALL (2.3%) also had DS, figures similar to those previously reported in population-based studies, and this enabled us to compare drug sensitivity in tumor cells from DS and non-DS children.
Leukemic cells from fresh bone marrow or blood samples were assessed for their in vitro drug sensitivity by the fluorometric microculture cytotoxicity assay (FMCA) against a panel of drugs used in the current Nordic protocols for AML 2 and ALL, 5 respectively. The FMCA is a non-clonogenic assay, very similar to the more widely used MTT assay, 6 and is based on the measurement of fluorescence generated from hydrolysis of fluorescein diacetate to fluorescein by cells with intact plasma membranes.
7 A survival index (SI) was calculated as the fluorescence signal of cells after 72 h of drug incubation as a percentage of that of unexposed controls.
Leukemic cells from DS children with AML were significantly more sensitive (P = 0.03-0.002) than blast cells from non-DS children to cytosine arabinoside (Ara-C), doxorubicin, dexamethasone (see Figure  1a) and amsacrine (not shown). A trend in the same direction was found for etoposide (VP16) and 6-thioguanine. DS patients with AML were significantly younger (mean 2.1 years) than non-DS patients (7.9 years), but a statistically significant difference was found also when comparing the DS samples with those of age-matched controls, and there was no clear correlation between age and in vitro sensitivity among non-DS patients with AML.
Three Down patients had FAB subtype M1 and two had M7 AML. In contrast, leukemic cells from DS children with ALL were significantly less sensitive (P = 0.02-0.001) than cells from non-DS patients to dexamethasone and asparaginase, with a similar trend for vincristine, doxorubicin and Ara-C (Figure 1b) . The mean age for DS children with ALL was 10.8 years and for non-DS patients 6.5 years (NS). Two DS patients fulfilled standard risk and three intermediate risk criteria according to the Nordic ALL protocol.
Findings similar to ours have previously been described in DS children with AML, 8, 9 while in ALL a single study on six DS patients showed no significant differences for most drugs tested (ALL cells of DS patients were slightly more sensitive to anthracyclines).
9
The inferior clinical outcome in ALL has been attributed to excessive therapy-related toxicity in DS children, but this would not explain the difference between AML and ALL. Our data, which have to be confirmed in larger series of patients, indicate that at least part of the explanation for the differences in clinical outcome between DS and non-DS children should be sought among mechanisms for tumor cell drug resistance. The fact that the difference in drug sensitivity between DS and other children was diametrically opposed for AML and ALL, suggests cell lineage-specific rather than general cellular alterations 
Figure 1
In vitro sensitivity of leukemic blast cells from children with Down's syndrome and acute myeloid leukemia (AML; n = 5), upper panel, or acute lymphoblastic leukemia (ALL; n = 5), lower panel, compared to non-Down children with leukemia (n = 57 and 217, respectively). SI denotes surviving cells, in percentage of untreated control, after 72 h incubation with cytosine arabinoside 0.5 g/ml (Ara-C), doxorubicin 0.5 g/ml (Dox), etoposide 5 g/ml (VP16), 6-thioguanine 10 g/ml (6-TG), dexamethasone 7.1 g/ml (Dexa), vincristine 0.5 g/ml (Vcr), asparaginase 10 U/ml (Asp). The results are presented as mean values plus s.e.m. The statistical significance levels (Student's t-test) are indicated; NS, non-significant. associated with the presence of three copies of chromosome 21 as suggested by Taub et al. 8 Presently, we do not understand the mechanism(s) behind the differences in drug sensitivity between DS and non-DS children, but we think our data point at an area for further fruitful research.
